人民财讯7月31日电，金城医药（300233）7月31日晚间公告，公司之全资子公司北京金城泰尔制药有限 公司(简称"金城泰尔")于近日收到韩国食品药品安全部下发的普罗雌烯乳膏药品进口许可证。普罗雌烯 是当前唯一上市的严格局部作用的雌激素。 ...

山东金城医药集团股份有限公司 关于子公司获得韩国药品进口许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司北京金城泰尔制药有限公司 （以下简称"金城泰尔"）于近日收到韩国食品药品安全部（以下简称"韩国 MFDS"）下发的普罗雌烯乳膏药品进口许可证，现将相关情况公告如下： 一、证书基本信息 企业名称：北京金城泰尔制药有限公司 证券代码：300233 证券简称：金城医药 公告编号：2025-053 普罗雌烯是当前唯一上市的严格局部作用的雌激素，用于外阴、前庭部及 阴道环部的萎缩性病变，以及由此引发的以下自觉症状：不适、外阴瘙痒、灼 热、干燥。这类疾病均因女性在绝经过渡期及绝经后期妇女因雌激素和其他性 激素水平降低引起的，统称绝经生殖泌尿综合征（以下简称"GSM"）。国内外 相关指南将局部使用雌激素作为治疗 GSM 的首选方案，普罗雌烯乳膏为该方案 品种之一，作为严格局部作用的雌激素，该产品不刺激子宫内膜增生，没有增 加血雌激素水平的潜在风险。根据 IMS 数据查询，2022 年至 2024 年普罗雌烯制 剂全球销 ...

Group 1: Company Performance - WuXi AppTec reported a net profit of 8.561 billion yuan for the first half of the year, a year-on-year increase of 101.92% [1] - The company's revenue for the first half reached 20.799 billion yuan, reflecting a growth of 20.64% year-on-year [1] - WuXi AppTec plans to distribute a cash dividend of 3.5 yuan per share to all shareholders [1] - The company has revised its revenue forecast for the full year to between 42.5 billion and 43.5 billion yuan [1] - SANY Heavy Industry plans to issue non-financial corporate debt financing tools not exceeding 20 billion yuan to optimize its financing structure [1] Group 2: Film Industry Impact - Happiness Blue Sea announced that the film "Nanjing Photo Studio" has surpassed 412 million yuan in cumulative box office, exceeding 50% of the company's audited revenue for the most recent fiscal year [2] - The film's impact on the company's revenue is currently negligible as it is still in theaters [2] Group 3: Corporate Actions - Zhonghua Equipment plans to issue shares to acquire 100% equity of two companies, marking a significant asset restructuring [2] - Dahua Intelligent is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [3] - Shiming Technology's actual controller and chairman has been placed under detention due to personal matters unrelated to the company [4] Group 4: Financial Performance - Ju Chen Co. reported a net profit growth of 43.5% for the first half of the year [6] - Qizheng Tibetan Medicine's net profit increased by 9.94% year-on-year [6] - China Minmetals' new contract value decreased by 19.1% year-on-year [6] - Huicheng Environmental's net profit declined by 85.63% year-on-year [6] Group 5: Mergers and Acquisitions - Kaishan Holdings plans to acquire a minority stake in SMGP for 3 million USD [6] - Zhonghua International intends to purchase 100% equity of Nantong Xingchen Composite Materials Co., Ltd. [6] - Xiangdian Co. plans to acquire a 12.5% stake in Tongda Electromagnetic Energy for 208 million yuan [6]

证券代码：300233 证券简称：金城医药 公告编号：2025-052 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司北京金城泰尔制药有限公司 （以下简称"金城泰尔"）于近日收到欧洲药品质量管理局（EDQM）核准签发的 磷酸奥司他韦化学原料药欧洲药典适用性证书(以下简称"CEP 证书"），现将相 关情况公告如下： 一、药品基本情况 化学原料药名称：磷酸奥司他韦 生产企业：北京金城泰尔制药有限公司 证书生效日期：2025 年 7 月 25 日 证书编号：CEP 2023-418 – Rev 00 二、药品相关信息 磷酸奥司他韦是一种选择性的流感病毒神经氨酸酶抑制剂，可以抑制病毒在 体内进一步扩散，由罗氏公司研制开发。目前国内磷酸奥司他韦的相关剂型为胶 囊、颗粒剂和干混悬剂，临床上主要适用于成人、1 岁及 1 岁以上儿童的甲型和乙 型流感治疗，成人、13 岁及 13 岁以上青少年的甲型和乙型流感的预防。根据 IMS 数据查询，2023 年全球制剂销售额 8.74 亿美元，原料药消耗 69.99 吨。2024 年 全球制剂销 ...

Group 1 - The genetically modified concept sector rose by 3.15%, ranking 7th among concept sectors, with 18 stocks increasing, including Shennong Seed Industry which hit the daily limit of 20% [1] - The main inflow of funds into the genetically modified concept sector was 459 million yuan, with 13 stocks receiving net inflows, and 8 stocks seeing inflows exceeding 10 million yuan [2] - Shennong Seed Industry led the net inflow of funds with 292 million yuan, followed by Qianyuan High-Tech, Jincheng Pharmaceutical, and Top Cloud Agriculture [2][3] Group 2 - The top stocks by net inflow ratio included Shennong Seed Industry at 11.98%, Qianyuan High-Tech at 10.45%, and Nongfa Seed Industry at 10.05% [3] - The trading volume and turnover rates for leading stocks were significant, with Shennong Seed Industry showing a turnover rate of 53.68% [3][4] - Other notable stocks included Jincheng Pharmaceutical and Top Cloud Agriculture, with net inflows of 26.61 million yuan and 24.76 million yuan respectively [3]

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

证券代码：300233 证券简称：金城医药 公告编号：2025-051 山东金城医药集团股份有限公司 关于全资子公司烟草专卖生产企业许可证续期及变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）之全资子公司山东金 城医药化工有限公司（以下简称"金城医化"）于 2025 年 7 月 18 日收到国家烟 草专卖局下发的《烟草专卖生产企业许可证》（电子烟用烟碱生产企业）。本次 下发的《烟草专卖生产企业许可证》将有效期延长至 2028 年 06 月 30 日，并对原 许可证的相关内容进行了变更，现将具体情况公告如下： 一、许可证的主要内容 1、企业名称：山东金城医药化工有限公司 2、许可证编号：3137030055 3、企业住所（主要经营场所、经营场所）：山东省淄博市淄川区昆仑镇晟地 路 288 号 4、法定代表人：韩振友 5、企业类型：有限责任公司（非自然人投资或控股的法人独资） 6、许可范围：电子烟用烟碱生产（内销）；电子烟用烟碱生产（出口） 7、主要出资人：山东金城医药集团股份有限公司（出资比例 100. ...

一、本次质押展期情况 二、股东股份累计质押情况 | | | | | | | 占公 | | 已质押股份情况 未质押股份情况 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次变动前 | 本次展期后 | 占其所 | 司总 | 已质押 | | | 占未 | | 股东 | 持股数量 | 持股比 | | | 持股份 | | 股份限 | | 未质押股 | | | | | | 质押股份数 | 质押股份数 | | 股本 | | 占已质押 | | 质押 | | 名称 | （股） | 例（%） | | | 比例 | | 售和冻 | | 份限售和 | | | | | | 量（股） | 量（股） | （%） | 比例 | 结、标记 | 股份比例 | 冻结数量 | 股份 | | | | | | | | （%） | | （%） | | 比例 | | | | | | | | | 数量 | | （股） | （%） | | | | | | | | | （股） | | | | 关于控股股东部分股份质押展期的公告 本公司及董事会全 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-049 山东金城医药集团股份有限公司 关于子公司收到药品 GMP 符合性检查告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）收到北京市药品监督管理局核准签发的《药品 GMP 符合性 检查告知书》（京药监药 GMP〔2025〕020026），现就相关情况公告如下： 一、《药品 GMP 符合性检查告知书》相关信息 企业名称：北京金城泰尔制药有限公司 检查地址：河北省沧州市临港经济技术开发区西区北京医药产业园经五路以 东纬二路以北 检查范围及相关生产车间、生产线：河北省沧州市临港经济技术开发区西区 北京医药产业园经五路以东纬二路以北，原料药富马酸比索洛尔(包装规 格:10kg/桶，批准文号:国药准字 H20057558，登记号:Y20190005788，二车间， 富马酸比索洛尔生产线。 检查类型：依企业申请开展的药品 GMP 符合性检查 二、对公司的影响及风险提示 金城泰尔本次顺利通过药品 GMP 符合 ...

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference was held in Beijing from July 5 to 7, organized by the China Pharmaceutical Industry Information Center, which released the list of the top 100 companies by main business revenue for 2024 [1] - China National Pharmaceutical Group continues to rank first, followed by China Resources Pharmaceutical and Qilu Pharmaceutical in second and third places respectively [1] - The conference theme was "Exploring Life, Co-creating the Future," focusing on cutting-edge technology, industrial ecology, and capital empowerment to outline a development blueprint for the Chinese pharmaceutical health industry [1] Group 2 - The pharmaceutical industry in Zibo has over 70 years of development history, forming a comprehensive industrial system that includes drug formulations, active pharmaceutical ingredients, medical devices, and traditional Chinese medicine [2] - In 2024, Zibo's pharmaceutical industry is projected to achieve a revenue of 65 billion yuan with double-digit growth, demonstrating strong industry resilience and development potential [2] Group 3 - Shandong Xinhua Pharmaceutical Co., Ltd. ranked 37th, Ruiyang Pharmaceutical Co., Ltd. ranked 77th, Shandong Qidu Pharmaceutical Co., Ltd. ranked 83rd, and Shandong Jincheng Pharmaceutical Group Co., Ltd. ranked 96th in the top 100 list [1] - Compared to the previous year's rankings, Xinhua Pharmaceutical improved by 3 positions, Ruiyang Pharmaceutical dropped by 14 positions, Qidu Pharmaceutical improved by 4 positions, and Jincheng Pharmaceutical dropped by 5 positions [1]